Marinus Pharmaceuticals Inc (MRNS) was Downgraded by RBC Capital Mkts to ” Sector Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. RBC Capital Mkts advised their investors in a research report released on Jun 14, 2016.
Marinus Pharmaceuticals Inc closed down -0.25 points or -4.47% at $5.34 with 1,16,499 shares getting traded on Friday. Post opening the session at $5.42, the shares hit an intraday low of $5.25 and an intraday high of $5.47 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Feb 11, 2016, Christopher Michael Cashman (CEO) purchased 3,561 shares at $5.61 per share price. According to the SEC, on Apr 23, 2015, Gail M Farfel (Chief Clinical Dev & Reg Offic) sold 30,000 shares at $9.48 per share price.
Marinus Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate ganaxolone is a small molecule that is a synthetic analog of allopregnanolone which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Company’s indication for ganaxolone is as an adjunctive or add-on therapy for the treatment of partial also known as focal onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Company’s oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.